Medicare受益者在免疫实践咨询委员会推荐65岁及以上成人常规使用13价肺炎球菌结合疫苗和23价肺炎球菌多糖疫苗后接种肺炎球菌疫苗的情况
美国CDC分析了2009年9月19日至2016年9月18日期间持续参加Medicare A和B部分的65岁及以上受益者的疫苗接种报销索赔,以估计ACIP修订推荐前后PCV13和PPSV23的接种覆盖率。截至2016年9月18日,43.2%的受益者有至少1剂PPSV23的索赔,31.5%有至少1剂PCV13的索赔,18.3%同时有PCV13和PPSV23各至少1剂的索赔;接种索赔在年龄较大、白人或有慢性及免疫抑制疾病的受益者中更高。实施国家疫苗咨询委员会成人免疫实践标准可能有助于提高肺炎球菌疫苗接种覆盖率。
要点
- 截至2016年9月18日,43.2%的65岁及以上Medicare受益者有至少1剂PPSV23的索赔。
- 31.5%有至少1剂PCV13的索赔,18.3%同时有PCV13和PPSV23各至少1剂的索赔。
- 接种索赔在年龄较大、白人或有慢性及免疫抑制疾病的受益者中高于健康成人。
核心结论
- 截至2016年9月18日,65岁及以上Medicare受益者中PCV13和PPSV23的接种覆盖率分别为31.5%和43.2%,同时接种两种疫苗者仅18.3%。
研究设计与样本
- CDC分析了2009年9月19日至2016年9月18日年度期间持续参加Medicare A和B部分的65岁及以上受益者的疫苗接种报销索赔。
主要发现
- 截至2016年9月18日,43.2%的受益者有至少1剂PPSV23的索赔(不论PCV13状态)。
- 31.5%的受益者有至少1剂PCV13的索赔(不论PPSV23状态)。
- 18.3%的受益者有PCV13和PPSV23各至少1剂的索赔。
- 接种索赔在年龄较大、白人或有慢性及免疫抑制疾病的受益者中高于健康成人。
关键数值与推荐
- 2014年9月19日,CDC发布ACIP推荐,65岁及以上成人常规使用PCV13并与PPSV23序贯接种,取代了此前仅接种单剂PPSV23的推荐。
临床怎么用
- 实施国家疫苗咨询委员会成人免疫实践标准(每次就诊评估接种状态、推荐所需疫苗、接种或转诊至接种提供者)可能有助于提高肺炎球菌疫苗接种覆盖率并降低老年人肺炎和侵袭性肺炎球菌病风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On September 19, 2014, CDC published the Advisory Committee on Immunization Practices (ACIP) recommendation for the routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged ≥65 years, to be used in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (1). This replaced the previous recommendation that adults aged ≥65 years should be vaccinated with a single dose of PPSV23. As a proxy for estimating PCV13 and PPSV23 vaccination coverage among adults aged ≥65 years before and after implementation of these revised recommendations, CDC analyzed claims for vaccination submitted for reimbursement to the Centers for Medicare & Medicaid Services (CMS). Claims from any time during a beneficiary's enrollment in Medicare Parts A (hospital insurance) and B (medical insurance) since reaching age 65 years were assessed among beneficiaries continuously enrolled in Medicare Parts A and B during annual periods from September 19, 2009, through September 18, 2016. By September 18, 2016, 43.2% of Medicare beneficiaries aged ≥65 years had claims for at least 1 dose of PPSV23 (regardless of PCV13 status), 31.5% had claims for at least 1 dose of PCV13 (regardless of PPSV23 status), and 18.3% had claims for at least 1 dose each of PCV13 and PPSV23. Claims for either type of pneumococcal vaccine were highest among beneficiaries who were older, white, or with chronic and immunocompromising medical conditions than among healthy adults. Implementation of the National Vaccine Advisory Committee's standards for adult immunization practice to assess vaccination status at every patient encounter, recommend needed vaccines, and administer vaccination or refer to a vaccinating provider might help increase pneumococcal vaccination coverage and reduce the risk for pneumonia and invasive pneumococcal disease among older adults (2).
引用
- Black CL, Williams WW, Warnock R, et al. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years. MMWR Morb Mortal Wkly Rep. 2017. PMID: 28704347. doi:10.15585/mmwr.mm6627a4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。